And the highest funding in Europe this year goes to… Antibody-Drug Conjugates!

19/10/2016 - 3 minutes

AstraZeneca has contributed to ADC Therapeutics’ €96M fundraising, the biggest round so far in Europe this year. Will this huge investment pay out for the British-Swedish Big Pharma? 

logo adctADC Therapeutics (ADCT) is a Swiss Biotech that develops antibody-drug conjugates (ADCs) for oncology applications. Its founder Auven Therapeutics and its partner AstraZeneca have participated in the biggest funding round of the year in Europe: a whopping €96M.

ADCT plans to use the funds to advance nothing less than 6 clinical programs in the next 18 months. Two of their candidates, ADCT-301 and ADCT-402, are already in Phase Ia. Both are being tested to treat sub-types of lymphoma and leukemia.

And what is this exciting technology that draws the attention of big Pharma? ADCs are monoclonal antibodies that are linked to a toxin. By targeting the antibodies to specific tumor antigens, the toxin can selectively kill cancer cells.

ADCT employs pyrrolobenzodiazepine (PBD) dimer toxins from MedImmune, AstraZeneca’s R&D arm. These molecules interact with DNA to block cell division without being caught by DNA repair mechanisms,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member